- For Print
- December 2, 2014
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that new clinical study results on the company's novel anticancer agent Halaven® (eribulin mesylate) will be presented during the 37th San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 9 through 13, 2014, in San Antonio, Texas in the United States.
The studies reflect Eisai's current and ongoing research efforts to establish the clinical benefits of Halaven and maximize the drug's value. The studies to be presented at this year's SABCS highlight the company's current oncology product portfolio strategy and research accomplishments in this field.
Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research in order to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.
The following Eisai abstracts are accepted for presentation at this year's SABCS:
*You can scroll to the left or right here
| Product | Abstract name and scheduled presentation date and time (local time) |
|---|---|
Halaven |
Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, Phase Ⅱ dose-confirmation study |
Halaven |
Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis |
Halaven |
Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC Poster Session | December 12 (Fri), 17:00-19:00 |
Halaven |
Quality of life results from a Phase Ⅱ, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer |
Halaven |
Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal ER+ early-stage breast cancer: A Phase Ⅱ, multicenter, open-label study using 2 different dosage regimens |